CNS Pharmaceuticals Inc
$ 4.59
-6.13%
09 Jun - close price
- Market Cap 7,307,200 USD
- Current Price $ 4.59
- High / Low $ 4.85 / 4.59
- Stock P/E N/A
- Book Value 0.09
- EPS -24.12
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.13 %
- ROE -2.99 %
- 52 Week High 12.36
- 52 Week Low 1.90
About
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central nervous system tumors. The company is headquartered in Houston, Texas.
Analyst Target Price
$10.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-31 | 2025-11-14 | 2025-08-14 | 2025-04-30 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-01 | 2024-03-14 | 2023-11-14 | 2023-08-14 |
| Reported EPS | -7.3 | -10.15 | -5.76 | -6.42 | -2.2471 | -37.33 | -0.2527 | -6.7192 | -0.4068 | -28622.9609 | -2.7 | -1.0371 |
| Estimated EPS | -5.37 | -5.09 | -0.63 | -9.6 | -2 | -7.33 | -0.1 | None | None | None | -2.4 | None |
| Surprise | -1.93 | -5.06 | -5.13 | 3.18 | -0.2471 | -30 | -0.1527 | 0 | 0 | 0 | -0.3 | 0 |
| Surprise Percentage | -35.9404% | -99.4106% | -814.2857% | 33.125% | -12.355% | -409.2769% | -152.7% | None% | None% | None% | -12.5% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CNSP
2026-06-09 17:09:37
CNS Pharmaceuticals (NASDAQ: CNSP) announced that its CFO discussed the company's recently oversubscribed $22.5 million financing in a virtual investor segment. The presentation covered the factors behind the successful capital raise following a strategic reset and acquisition-focused transformation, along with investor reception to their evolving strategy. The company emphasized how the strengthened balance sheet supports its pursuit of transformational opportunities and long-term growth.
2026-06-08 14:39:49
CNS Pharmaceuticals' CFO, Steve O'Loughlin, provided insights into the company's recent oversubscribed $22.5 million financing during a Virtual Investor "What This Means" segment. He discussed the factors contributing to the successful capital raise, investor reception to the company's evolving strategy, and the significance of institutional investor participation. The financing strengthens CNS Pharmaceuticals' balance sheet, enabling it to pursue transformational opportunities and advance its long-term vision for shareholder value.
2026-06-08 13:39:48
CNS Pharmaceuticals' CFO, Steve O'Loughlin, discussed the company's oversubscribed $22.5 million financing in a Virtual Investor segment. He highlighted the strategic reset, acquisition-focused transformation, and the strengthened balance sheet intended to pursue new opportunities and enhance shareholder value. The discussion also covered participation from leading healthcare-focused institutional investors and the positive investor reception to the company's evolving strategy.
2026-05-27 10:10:53
This SEC filing announces that the S-3 shelf registration statement for CNS Pharmaceuticals, Inc. became effective on May 26, 2026, at 4:00 PM. The filing is categorized as "Neutral" in both impact and sentiment. It also provides an overview of the company's recent news and SEC filings.
2026-05-26 21:09:23
CNS Pharmaceuticals (NASDAQ: CNSP) has registered up to 9.79 million shares of common stock for resale by selling shareholders. These shares originate from a private placement in May 2026, including common stock and shares issuable upon exercising pre-funded warrants. The company will not receive proceeds from the resale of these shares, having already received approximately $22.5 million in gross proceeds from the initial private placement.
2026-05-22 15:09:24
This page provides a comprehensive resource for CNS Pharmaceuticals (CNSP) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details regulatory records for the company, which develops therapies for brain and central nervous system cancers. The filings cover various updates, disclosures, and governance matters, with the most recent filing on August 15, 2025.
